Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
Provided are methods for preparing sterilized, gelled, solubilized extracellular matrix (ECM) compositions useful as cell growth substrates. Also provided are compositions prepared according to the methods as well as uses for the compositions. In one embodiment a device, such as a prosthesis, is provided which comprises an inorganic matrix into which the gelled, solubilized ECM is dispersed to facilitate in-growth of cells into the ECM and thus adaptation and/or attachment of the device to a patient.
1. A method of preparing an extracellular matrix-derived gel comprising, in order: (i) solubilizing extracellular matrix (ECM) that has not been dialyzed by digestion with an acid protease in an acidic solution to produce a digest solution, (ii) drying the digest solution, and (iii) terminally sterilizing the dried digest.
2. The method of claim 1 , further comprising:
(iv) hydrating and neutralizing the sterilized dried digest to a pH between 7.2 and 7.8 to produce a neutralized digest solution, and (v) gelling the solution at a temperature greater than 25 ° C.
3. The method of claim 1 , wherein the ECM is not terminally sterilized, dialyzed or subjected to a cross-linking process prior to the solubilizing step.
4. The method of claim 1 , wherein the digest solution is lyophilized.
5. The method of claim 1 , wherein the dried digest is sterilized using gamma radiation, electron beam radiation, ethylene oxide and/or supercritical CO 2 .
6. The method of claim 1 , wherein the ECM is derived from mammalian tissue.
7. The method of claim 6 , wherein the mammalian tissue is derived from one of urinary bladder, spleen, liver, heart, central nervous system, adipose tissue, bone, pancreas, ovary, small intestine, large intestine, or colon.
8. The method of claim 1 , wherein the ECM is comminuted.
9. The method of claim 2 , wherein the neutralized digest solution is maintained at or below 25° C. before gelation.
10. The method of claim 1 , wherein the acid protease is pepsin.
11. The method of claim 10 , wherein the ECM is solubilized at a pH of 2 or higher, or at a pH between 3 and 4.
12. The method of claim 2 , wherein the digest solution is gelled at 30° C. or higher.
13. The method of claim 2 , further comprising administering the neutralized digest solution to a patient and wherein the gelling takes place in or on the patient.
14. The method of claim 13 , wherein the pH of digest solution is raised by mixing the digest solution with a base or a buffer during administration to the patient.
15. The method of claim 2 , further comprising integrating one or more of a cell, a drug, a cytokine, and a growth factor into the gel.
16. The method of claim 2 , further comprising coating a matrix of a biocompatible scaffold with the solubilized ECM and gelling the matrix.
17. The method of claim 16 , wherein the biocompatible scaffold is coated either with the digest solution between the steps of solubilizing the ECM and drying the digest solution or with either the sterilized digest solution or the neutralized digest solution after the step of hydrating the digest solution and before the neutralized digest solution is gelled.
18. The method of claim 17 , wherein the biocompatible scaffold comprises:
(a) one or more of a cobalt-chrome alloy, a stainless steel, titanium, tantalum, and/or a titanium alloy, that optionally comprises non-metallic and metallic components;
(b) an inorganic mineral comprising calcium;
(c) a ceramic; and/or
(d) a polymer.
19. The method of claim 17 , wherein the biocompatible scaffold comprises filaments or fused beads.